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The objective of this study was to determine the eﬀect of AVE7688, a drug that inhibits both angiotensin converting enzyme (ACE)
and neutral endopeptidase (NEP) activity, on neural and vascular defects caused by diet induced obesity (DIO). Rats at 12 weeks
of age were fed a standard or high fat diet with or without AVE7688 for 24 weeks. DIO rats had impaired glucose tolerance
and developed sensory neuropathy. Vascular relaxation to acetylcholine and calcitonin gene-related peptide was decreased in
epineurial arterioles of DIO rats. Rats fed a high fat diet containing AVE7688 did not become obese and vascular and sensory
nervedysfunctionandimpairedglucosetolerancewereimproved.DIOisassociatedwithincreasedexpressionofNEPinepineurial
arterioles. NEP degrades vasoactive peptides which may explain the decrease in neurovascular function in DIO.
1.Introduction
Previously, we demonstrated that high-fat fed rats, a model
for diet-induced obesity, develop microvascular and neu-
ral deﬁcits independent of hyperglycemia and this was
accompanied by an increase in the expression of neutral
endopeptidase in epineurial arterioles, vessels that provide
circulation to the sciatic nerve [1]. In the present study,
we sought to determine whether treatment of high-fat fed
rats with AVE7688, a vasopeptidase inhibitor, for 24 weeks
beginning at 12 weeks of age could improve microvascular
dysfunction and prevent the slowing of sensory nerve
conduction velocity. Vasopeptidase inhibitors are a new class
of drugs that simultaneously inhibits neutral endopeptidase
(NEP) and angiotensin converting enzyme (ACE) activity
[2]. Recent studies have shown increased expression of
angiotensin II-forming enzymes in adipose tissue, and
increased activity of the renin-angiotensin system has been
implicated in the development of insulin resistance and type
2 diabetes [3]. Neutral endopeptidase is found in many
tissues including vascular and nerve tissue and its activity is
increased by fatty acids and glucose in human microvascular
cells [4–8]. Neutral endopeptidase degrades many vasoactive
peptides including natriuretic peptides, adrenomedullin,
bradykinin, and calcitonin gene-related peptide [9, 10].
Therefore, inhibition of ACE and NEP activity would be
expected to improve vascular function. In this regard, we
have demonstrated that treating type 1 and type 2 diabetic
rats as well as a genetic rat model of obesity with AVE7688
improvesvascularandneuraldysfunction[11–13].However,
no information is available about the eﬀect of vasopeptidase
inhibitors in an animal model of diet-induced obesity.
2.MaterialsandMethods
Unless stated otherwise, all chemicals used in these studies
were obtained from Sigma Chemical Co. (St. Louis, MO).
2.1. Animals. Male Sprague-Dawley (Harlan Sprague Daw-
ley, Indianapolis, IN) rats 10-11 weeks of age were housed
in a certiﬁed animal care facility and food (Harlan Teklad,
#7001, Madison, WI) and water were provided ad libitum.
All institutional (ACURF #0691101), VAMC, and NIH
guidelines for use of animals were followed. At 12 weeks
of age the rats were weighed and randomly divided into
six groups. One group was maintained on a normal diet.2 Journal of Obesity
A second group was maintained on a normal diet containing
500mg/kg AVE7688 (Ilepatril, Sanoﬁ Aventis). Group 3 was
placed on a high-fat diet. Group 4 was placed on a high-
fat diet containing 500mg/kg AVE7688, which inhibits both
ACE and NEP activity. In order to determine the role of
ACE and NEP inhibition independently rats (Groups 5 and
6) were fed a high-fat diet containing Enalapril (500mg/kg,
ACE inhibitor) or Candoxatril (300mg/kg, NEP inhibitor),
respectively.Thehigh-fatdietcontained24gm%fat,24gm%
protein, and 41gm% carbohydrate (D12451; Research Diets,
New Brunswick, NJ). The primary source of the increased
fat content in the diet was soybean oil and lard. The average
fat content of the control diet was 4.25gm% (Harlan Teklad,
#7001, Madison, WI).
2.2. Glucose Tolerance. Glucose tolerance was determined by
injectingratswithasalinesolutioncontaining2g/kgglucose,
i.p., after an overnight fast. Immediately prior to the glucose
injection and for 240 minutes afterwards blood samples were
taken to measure circulating glucose levels using glucose
oxidase reagent strips (Lifescan Inc., Milpitas, CA). Fasting
basal levels of insulin and leptin was also determined using
Luminex technology.
2.3. Thermal Nociceptive Response. The day before termi-
nal studies, thermal nociceptive response in the hindpaw
was measured using the Hargreaves method as previously
described [14].
2.4. Motor and Sensory Nerve Conduction Velocity and Bio-
logical and Oxidative Stress Markers. On the day of terminal
studies, rats were weighed and anesthetized with Nembutal
i.p. (50mg/kg, i.p., Abbott Laboratories, North Chicago,
IL). Serum samples were collected for determination of
free fatty acid, triglyceride, free cholesterol, adiponectin,
8-hydroxy deoxyguanosine (8-OH DG), and angiotensin
converting enzyme activity, using commercial kits from
Roche Diagnostics, Mannheim, Germany; Sigma Chemical
Co., St. Louis, MO; Bio Vision, Mountain View, CA; ALPCO
diagnostics, Windham, NH, Cell Biolabs, Inc., San Diego,
CA; ALPCO diagnostics, Windham, NH, respectively. Serum
thiobarbituric acid reactive substances (TBARS) levels were
also determined as an additional marker of oxidative stress
as previously described [15].
Motor and sensory nerve conduction velocity was deter-
mined as previously described and afterwards the left gas-
trocnemius muscle, epididymal fat pad, interscalpel brown
fat pad, and tissue containing the epineurial arterioles was
collected [16–18]. The gastrocnemius muscle, epididymal fat
pad and interscalpel brown fat pad were weighed.
2.5. Intraepidermal Nerve Fiber Density in the Hindpaw.
Immunoreactive intraepidermal nerve ﬁber proﬁles were
visualized using confocal microscopy. Samples of skin of
the right hindpaw were ﬁxed, dehydrated, and embedded in
paraﬃn. Sections (7μm) were collected and immunostained
with anti-PGP9.5 antibody (rabbit antihuman, AbD serotic,
Morpho Sys US Inc., Raleigh, NC) over night followed by
treatment with secondary antibody Alexa Fluor 546 goat
antirabbit (Invitrogen, Eugene, OR). Proﬁles were counted
by two individual investigators that were blinded to the
sample identity. All immunoreactive proﬁles within the
epidermis were counted and normalized to epidermal length
[1, 19].
2.6. Vascular Reactivity. Videomicroscopy was used to inves-
tigate in vitro vasodilatory responsiveness of arterioles
vascularizing the region of the sciatic nerve as previously
described [1, 16, 17]. Cumulative concentration-response
relationshipswereevaluatedforacetylcholine(10−8–10−4 M)
and calcitonin gene-related peptide (10−11–10−8 M) (CGRP)
using vessels from each group of rats. At the end of the
acetylcholine concentration response curve a maximal dose
of sodium nitroprusside (10−4 M) was added in order to
determine the endothelium-independent relaxation poten-
tial. At the end of each dose response curve for acetylcholine
or CGRP papaverine (10−5 M) was added to determine
maximal vasodilation.
2.7. Data Analysis. Results are presented as mean ± SEM.
Comparisons between the groups were conducted using
one-way ANOVA and Bonferroni post-test (Prism software;
GraphPad, San Diego, CA). Concentration response curves
for acetylcholine and CGRP were compared using a two-way
repeated measures analysis of variance with autoregressive
covariance structure using proc mixed program of SAS [16,
17]. A P-value of less than .05 was considered signiﬁcant.
3. Results
3.1. Eﬀect of AVE7688 Treatment on Weight and Metabolic
P a r a m e t e r sI n d u c e db yaH i g h - F a tD i e t . Sprague Dawley rats
at 12 weeks of age were placed on a normal diet with or
without 500mg/kg AVE7688 or a high-fat diet (45% kcal fat)
with or without AVE7688, Enalapril, or Candoxatril for 24
weeks. During the course of the study the rats on the control
diet ate 54g/kg rat/day and the rats on the high-fat diet or
high-fat diet containing AVE7688, Enalapril, or Candoxatril
ate33,35,33or32g/day/kgrat,respectively.Attheendofthe
study period rats on the high-fat diet weighed signiﬁcantly
more then rats on the control diet (Table 1). However, high-
fat fed rats treated with AVE7688 or Enalapril weighed
signiﬁcantly less than the high-fat fed rats. In contrast, high-
fat fed rats treated with Candoxatril weighed signiﬁcantly
more than the control or high-fat fed rats. All groups of
rats weighed approximately the same at the beginning of the
study and nonfasting blood glucose levels at the end of the
study were similar for rats in all six groups. Adding AVE7688
tothecontroldietalsoreducedweightgainover24weeksbut
this diﬀerence was not signiﬁcant compared to control. The
weight of the left gastrocnemius muscle was not diﬀerent for
the 6 groups of rats. In contrast, weight of the epididymal fat
pad was signiﬁcantly increased in high-fat fed rats and high-
fat fed rats treated with Enalapril or Candoxatril compared
to control. Weight of the epididymal fat pad was signiﬁcantly
less in rats fed a high-fat diet containing AVE7688 orJournal of Obesity 3
Table 1: Eﬀect of high-fat diet ± AVE7688, Enalapril or Candoxatril on blood glucose and change in body weight, fat pad and muscle mass.
Determination Control Control +
AVE7688
High Fat High Fat +
AVE7688
High Fat +
Enalapril
High Fat +
Candoxatril
(23) (8) (24) (28) (6) (6)
Start Body Weight (g) 338 ± 3 327 ± 5 340 ± 2 336 ± 3 353 ± 7 354 ± 4
End Body Weight (g) 485 ± 7 454 ± 5 560 ±9a 459 ±7b 495 ± 15b 643 ±20a,b
Blood glucose (mg/dL) 93 ± 6 93 ± 7 96 ± 6 88 ± 5 111 ± 6 116 ± 11
Epididymal fat pad (g) 5.6 ± 0.4 4.2 ± 0.2 12.0 ± 0.6a 6.5 ± 0.4b 8.3 ± 1.2a,b 17.3 ± 1.6a,b
Interscapular Brown fat pad (g) 0.38 ± 0.02 0.34 ± 0.03 0.68 ± 0.04a 0.44 ± 0.01b ND ND
Gastrocnemius muscle (g) 3.3 ± 0.1 3.2 ± 0.1 3.4 ± 0.1 3.1 ± 0.1 3.1 ± 0.1 3.6 ± 0.1
Data are presented as the mean ± SEM. aP <. 05 compared to control; bP <. 05 compared to high-fat. ND equals not determined. Parentheses indicate the
number of experimental animals in each group.
Enalapril, compared to high-fat fed rats.. The weight of the
interscapular brown fat pad was signiﬁcantly increased in
high-fat fed rats compared to control and this was prevented
whentheratsonthehigh-fatdietweretreatedwithAVE7688.
Serum was collected from rats fed the control, high-fat,
and high-fat with AVE7688, Enalapril, or Candoxatril diets
and used to measure a number of physiological parameters.
Data in Table 2 demonstrate that fasting insulin and leptin
levels are signiﬁcantly increased in rats fed a high-fat diet
and that this was prevented when the high-fat diet contained
AVE7688. Feeding rats a high-fat diet containing Enalapril
also signiﬁcantly reduced serum insulin levels and leptin
levels (but not signiﬁcantly) compared to high-fat fed rats.
Serum insulin and leptin levels were signiﬁcantly increased
in rats fed a high-fat diet containing Candoxatril compared
to control. Data in Figure 1 show that glucose tolerance was
impaired in high-fat fed rats compared to control rats and
this was improved by adding AVE7688 to the high-fat diet.
In contrast, adding Enalapril or Candoxatril to the high-fat
diet did not improve glucose tolerance. Combined these data
indicate that high-fat fed rats show signs of insulin resistant
and this can be prevented by AVE7688.
Serum cholesterol levels are signiﬁcantly increased in
high-fat fed rats and this was prevented by AVE7688,
Enalapril or Candoxatril (Table 2). Serum free fatty acids
and triglycerides levels are elevated in high-fat fed rats and
this was not prevented by adding AVE7688, Enalapril, or
Candoxatril to the high-fat diet (Table 2). Serum markers
for oxidative stress, 8-OH- deoxyguanosine and thiobar-
bituric acid reactive substances (TBARS) and adiponectin
are signiﬁcantly increased in rats fed a high-fat diet and
this was prevented by adding AVE7688 to the high-fat diet
(Table 2). Adding Enalapril or Candoxatril to the high-fat
diet reduced 8-OH- deoxyguanosine levels but not TBARS
levels. In contrast, adding Candoxatril to the high-fat diet
reduced both 8-OH- deoxyguanosine levels but not TBARS
levels.
3.2. Eﬀect of a High-Fat Diet and AVE7688 Treatment on
Neural and Vascular Function. Data in Figure 2 demonstrate
that sensory nerve conduction velocity was decreased in rats
fed a high-fat diet and this was prevented by AVE7688 and
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Figure 1: Eﬀect of a high-fat diet and treatment with AVE7688
on glucose tolerance. Rats were fed a standard or high-fat diet
with or without AVE7688, Enalapril, or Candoxatril for 24 weeks.
Afterwards glucose tolerance was determined as described in
Section. Data are presented as the mean ± SEM in mg/dL. The
area under the curve (AUC) was signiﬁcantly diﬀerent P<. 01 for
high-fat fed rats versus control. There was no signiﬁcant diﬀerence
for AUC between rats fed a high-fat diet containing AVE7688 and
control or high-fat fed rats. Feeding rats a high-fat diet containing
Enalapril or Candoxatril provided no improvement in impaired
glucose tolerance caused by the high-fat diet. The number of rats
in each group was the same as shown in Table 1.
Candoxatril treatment. Enalapril treatment of high-fat fed
rats also improved sensory nerve conduction velocity but
the diﬀerence between the high-fat fed group and Enalapril
treated group was not signiﬁcant. Motor nerve conduction
velocity was not signiﬁcantly aﬀected by high-fat diet or
treatments Data in Figure 3 demonstrate that rats fed a
high-fat diet for 24 weeks become thermal hypoalgesic and
that intraepidermal nerve ﬁber proﬁles in the hindpaw
are decreased (Figure 3) and these signiﬁcant changes are
prevented by adding AVE7688 to the high-fat diet. Adding4 Journal of Obesity
Table 2: Eﬀect of high fat diet ± AVE7688, Enalapril or Candoxatril on change in serum insulin, leptin, cholesterol, triglycerides, free fatty
acids, adiponectin, 8-hydroxy deoxyguanosine, TBARS, and ACE activity.
Determination Control High Fat High Fat + AVE7688 High Fat + Enalapril High Fat + Candoxatril
(23) (24) (28) (6) (6)
Insulin (ng/mL) 1.28 ±.09 3.60 ±0.43a 1.78 ±0.17b 0.67 ± 0.05b 3.74 ± 1.19a
Leptin (pM) 446 ± 81 2052 ± 389a 592 ±75b 1442 ± 430 2852 ± 260a
Cholesterol (mg/dL) 303 ± 31 680 ± 29a 347 ± 15b 201 ± 22b 255 ± 49
Triglycerides (mg/dL) 41.8 ± 4.1 71.5 ± 11.7 72.0 ± 9.1 67.3 ± 5.3 72.2 ± 8.9
Free fatty acids (mmol/L) 0.10 ± 0.01 0.20 ± 0.03a 0.21 ± 0.02a 0.28 ± 0.04a 0.20 ± 0.04
Adiponectin (μg/mL) 7.9 ± 0.6 11.0 ± 0.7a 9.5 ± 0.5 7.7 ± 0.7 7.8 ± 0.7
8-OH DG (ng/mL) 1.88 ± 0.10 2.58 ± 0.17a 1.91 ± 0.17b 1.85 ± 0.09 1.88 ± 0.14
TBARS (μg/mL) 0.13 ± 0.01 0.50 ± 0.07a 0.26 ± 0.05b 0.71 ± 0.03a 0.55 ± 0.02a
ACE activity (mU/mL/min) 94 ± 87 5 ± 62 3 ±2a,b 4 ±1a,b 111 ± 14
Data are presented as the mean ± SEM. aP <. 05 compared to control; bP <. 05 compared to high-fat. ND equals not determined. Parentheses indicate the
number of experimental animals in each group.
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Figure 2: Eﬀect of a high-fat diet and treatment with AVE7688
on motor and sensory nerve conduction velocity. Rats were fed a
standard or high-fat diet with or without AVE7688, Enalapril or
Candoxatril for 24 weeks. Data are presented as the mean ± SEM
for motor and sensory nerve conduction velocity in m/sec. The
number of rats in each group was the same as shown in Table 1.
∗P <. 05, compared to rats fed the standard diet (control), +P <
.05, compared to rats fed the high-fat diet.
Candoxatril to the high-fat diet also prevented the impair-
ment in thermal nociception and the signiﬁcant decrease in
intraepidermal nerve ﬁber proﬁles. Supplementing the high-
fat diet with Enalapril also improved thermal nociception
compared to high-fat fed rats but to a lesser extent than
AVE7688 or Candoxatril. In contrast, adding Enalapril
to the high-fat diet did not improve the reduction in
intraepidermal nerve ﬁber proﬁles compared to high-fat fed
rats.FeedingcontrolratsastandarddietcontainingAVE7688
did not aﬀect motor and sensory nerve conduction velocity,
thermal nociception or innervations, of the hindpaw (data
not shown).
Vascular relaxation in response to acetylcholine and
calcitonin gene-related peptide by epineurial arterioles from
high-fat fed rats are signiﬁcantly decreased compared to rats
fed a control diet or a high-fat diet containing AVE7688
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Figure 3: Eﬀect of a high-fat diet and treatment with AVE7688
on thermal nociception and intraepidermal nerve ﬁber proﬁles in
the hindpaw. Rats were fed a standard or high-fat diet with or
without AVE7688, Enalapril or Candoxatril for 24 weeks. Data are
presented as the mean ± SEM for thermal nociception in sec and
intraepidermal nerve ﬁber proﬁles per mm. The number of rats in
each group was the same as shown in Table 1.
∗P <. 05, compared
to rats fed the standard diet (control), +P <. 05, compared to rats
fed the high -fat diet.
(Figures 4 and 5, resp.). Treating rats with a high-fat diet
containing Enalapril, or Candoxatril also improved vascular
relaxation in response to acetylcholine and calcitonin gene-
related peptide with Candoxatril having a better eﬃcacy
than Enalapril. Feeding control rats a standard diet con-
taining AVE7688 did not aﬀect vascular reactivity activity in
epineurial arterioles (data not shown).
4. Discussion
Previously, we have demonstrated that treatment of types
1 and 2 diabetic rats and nondiabetic obese Zucker rats
with AVE7688, a vasopeptidase inhibitor, is eﬀective in
improving microvascular and neural complications [11–
13]. We have also reported that treatment of diabetic rats
with AVE7688 may be more eﬃcacious then monotherapyJournal of Obesity 5
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Figure 4: Eﬀect of a high-fat diet and treatment with AVE7688 on
acetylcholine-mediated vascular relaxation of epineurial arterioles.
Rats were fed a standard or high-fat diet with or without AVE7688,
Enalapril, or Candoxatril for 24 weeks. Pressurized arterioles
(40mm Hg and ranging from 60–100μm luminal diameter) were
constricted with U46619 (30%–50%) and incremental doses of
acetylcholine were added to the bathing solution while recording
steady state vessel diameter. Data are presented as the mean of %
relaxation ± SEM. For these studies, two vessels were collected from
each rat, studied, and the data combined. The number of rats in
each group was the same as shown in Table 1.
∗P <. 05, compared
to rats fed the standard diet (control), +P <. 05, compared to rats
fed the high-fat diet.
using an angiotensin converting enzyme inhibitor [20].
Given these results, we were interested in determining the
eﬀect AVE7688 treatment would have on microvascular
and neural complications in a rat model of diet-induced
obesity [1]. The primary hypothesis to be examined was
that treatment of rats fed a high-fat diet with AVE7688
will prevent vascular and neural dysfunction and that dual
inhibition of angiotensin converting enzyme and neutral
endopeptidase would be more eﬀective than monotherapy.
To test this hypothesis high-fat fed rats were treated with or
withoutAVE7688,Enalapril,orCandoxatril.After24weeksa
number of endpoints were examined to determine the eﬀect
of treatments on obesity related changes in weight, insulin
resistance, oxidative stress, and vascular and neural function.
The characteristics of the diet induced obesity rat
model are insulin resistance, impaired glucose intolerance,
dyslipidemiaandincreasedfatdepositbutnothyperglycemia
[21–26]. Studies have also demonstrated an increase in
oxidative stress [27, 28]. In a recent study, we found that
rats fed a high-fat diet develop sensory neuropathy as
indicated by slowing of sensory nerve conduction velocity,
thermal hypoalgesia, and decrease in intraepidermal nerve
ﬁber proﬁles. In contrast, endoneurial blood ﬂow of the
sciatic nerve and motor nerve conduction were not changed
[1]. We also found that relaxation of epineurial arterioles
to acetylcholine and CGRP was decreased in high-fat fed
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Figure 5: Eﬀect of a high-fat diet and treatment with AVE7688 on
calcitonin gene-related peptide-(CGRP)-mediated vascular relax-
ation of epineurial arterioles. Rats were fed a standard or high-
fat diet with or without AVE7688, Enalapril, or Candoxatril for 24
weeks. Arterioles were derived from rats as described in Figure 4.
Incremental doses of CGRP were added to the bathing solution
while recording steady state vessel diameter. Data are presented as
the mean of % relaxation ± SEM. The number of rats in each group
was the same as shown in Table 1.
∗P <. 05, compared to rats fed
thestandarddiet(control), +P <. 05,comparedtoratsfedthehigh-
fat diet.
rats, but unlike diabetic rats, oxidative stress in epineurial
arterioles was not increased [11, 12, 15, 16]. Moreover, we
found that expression and activity of neutral endopeptidase
in epineurial arterioles was increased in high-fat fed rats.
This led us to speculate that treating high-fat fed rats with
AVE7688 could be eﬃcacious in improving vascular and
neural defects associated with diet induced obesity. Since
AVE7688 is an inhibitor of both angiotensin converting
enzyme and neutral endopeptidase we also investigated the
role of Enalapril, an inhibitor of angiotensin converting
enzyme, and Candoxatril, an inhibitor of neutral endopep-
tidase, on weight gain and vascular and neural function in
rats fed a high-fat diet.
The most important ﬁndings of this study was that
rats fed a high-fat diet containing AVE7688 do not become
obese and treatment prevented development of the vascular
and neural dysfunction associated with diet induced obesity.
Treatment of high-fat fed rats with AVE7688 over a period
of 24 weeks using a prevention protocol prevented weight
gain and mass of white and brown fat pads from high-fat fed
rats treated with AVE7688 was signiﬁcantly less compared to
high-fatfedrats.Treatinghigh-fatfedratswithEnalaprilalso
reducedweightgainandtheweightofthe epididymal fatpad
was signiﬁcantly less compared to high-fat fed rats but was
also signiﬁcantly more than control rats. In contrast, treating
high-fat fed rats with Candoxatril caused a greater weight
gainandaccumulationofepididymal fatpadmasscompared
to high-fat fed rats. Analysis of glucose tolerance revealed6 Journal of Obesity
that treatment of high-fat fed rats with AVE7688 prevented
impairment of glucose utilization in rats fed a high-fat diet.
Glucose tolerance of high-fat fed rats treated with Enalapril
or Candoxatril remained signiﬁcantly impaired.
Previous studies have shown that diet induced obesity in
rodent models can be prevented by angiotensin converting
enzyme inhibitors and angiotensin II receptor blockers [29–
32]. In addition, diet induced weight gain and fat mass is
reduced,energyexpenditureincreased,andglucosetolerance
improved in mice lacking angiotensin converting enzyme
or the angiotensin II type 1a receptor [33, 34]. Therefore,
we were surprised to ﬁnd that glucose tolerance was not
improved in high-fat fed rats treated with Enalapril. Studies
showing improved insulin resistance with angiotensin con-
verting enzyme inhibitor treatment of chronic diet-induced
obesity have been done primarily with mice [30]. In rats
de Kloet et al. [35] demonstrated that Captopril treatment
of high-fat fed rats improved glucose tolerance. However,
the duration of the high-fat diet in this study was 35 days.
In comparison, the duration of high-fat diet in our study
was168days.Otherstudiesdemonstratingimprovedglucose
tolerance in rats treated with angiotensin converting enzyme
inhibitor were performed using rat models of type 2 diabetes
[36–38]. Therefore, the long term period of the high-fat
diet in our study may explain why we failed to see an
improvement in glucose tolerance in Enalapril treated high-
fat fed rats compared to the studies by de Kloet et al.
[35].
Treating high-fat fed rats with Candoxatril provided
no beneﬁt toward reducing weight gain and fat mass or
improving glucose tolerance. At the end of the study period,
weight gain and epididymal fat pad mass were signiﬁcantly
higher in Candoxatril treated high-fat fed rats compared
to high-fat fed rats. Therefore, inhibition of angiotensin
converting enzyme or neutral endopeptidase alone is not
suﬃcient to prevent obesity or insulin resistance in chronic
high-fat fed rats.
The mechanisms proposed for the improvement in obe-
sity and glucose tolerance with treatment of rodent models
with angiotensin converting enzyme inhibitors are increased
energy expenditure, liver and adipose tissue metabolic
modulation, lower concentration of leptin, improved insulin
signaling, and increased glucose and fatty acid utilization
by muscle [29–34, 37–42]. In a study comparing the eﬀects
of Ramipril, an angiotensin converting enzyme inhibitor,
to AVE7688 in JCR:LA-cp rats, an obese, insulin-resistant,
hyperinsulinemic, normoglycemic model, it was found that
both compounds reduced the surge of plasma insulin in a
meal tolerance test by about 50% but AVE7688 was more
beneﬁcial in improving vascular reactivity [43]. In another
study using obese Zucker rats, it was found that dual
inhibition of angiotensin converting enzyme and neutral
endopeptidase improved insulin mediated glucose disposal
more eﬀectively than monotherapy and this eﬀect was
linked to increased activation of the kinin-nitric oxide
pathway [44]. In a similar independent study, it was found
that Omapatrilat, a vasopeptidase inhibitor, induced insulin
sensitization and increased myocardial glucose uptake in
obese Zucker rats and that the eﬀect of Omapatrilat was
greater than Ramipril in part due to stimulation of the B2
receptor [45]. Later this group reported that treatment of
obese Zucker rats with a vasopeptidase inhibitor increased
muscle glucose uptake independent of insulin signaling [46].
In two of these studies, protection of bradykinin from
degradation by neutral endopeptidase was found to improve
insulin action [44, 45]. Interestingly, it has been shown
that natriuretic peptides promote muscle mitochondrial
biogenesis and fat oxidation as to prevent obesity and
glucose intolerance [47]. The natriuretic peptides are also
degraded by neutral endopeptidase [20]. Because neutral
endopeptidase is expressed in skeletal muscle in relatively
large amounts and being located on the cell surface, neutral
endopeptidase is able to hydrolyze peptides in the vicinity
of their receptors thereby neutralizing their bioactivity [20,
48]. Since bradykinin and natriuretic peptides may have
a role in regulating glucose and fatty acid metabolism by
muscle protecting, their bioactive function by preventing
degradation may be a therapeutic approach for treatment of
obesity and insulin resistance [20, 48].
The second major ﬁnding of this study was that treat-
ment of diet-induced obese rats with AVE7688 prevented
vascular and neural complications associated with obesity.
Previously, we reported that treatment of types 1 and
2 diabetic rat models with AVE7688 improved vascular
and neural complications and AVE7688 was more eﬀec-
tive than angiotensin converting enzyme inhibition [11–
13, 20]. In these studies, treating high-fat fed rats with
AVE7688 was generally more eﬃcacious then Enalapril
treatment in improving sensory neuropathy and vascular
relaxation to acetylcholine and calcitonin gene-related pep-
tide. We did not achieve signiﬁcant diﬀerences between the
AVE7688 and Enalapril treatment groups but we consistently
found that treatment with AVE7688 and Candoxatril had
better outcome for vascular and neural function than
Enalapril.
It is well known that patients with impaired glucose tol-
erance are at increased risk for myocardial infarction, stroke,
and large-vessel disease [49]. However, impaired glucose
tolerance is also independently associated with traditional
microvascular complications of diabetes including retinopa-
thy, nephropathy, and polyneuropathy. Several mechanisms
including inhibition of nitric oxide vasodilation, endothelial
injury from hyperlipidemia and cytokines, and increased
f o r m a t i o no fr e a c t i v eo x y g e ns p e c i e sh a v eb e e nc i t e da s
pathogenic causes for microvascular dysfunction associated
with obesity and insulin resistance [49, 50]. However, in
our studies with high-fat fed rats and examination of the
eﬀect on vascular reactivity of epineurial arterioles, we
have not been able to document an increase in reactive
oxygen species in these vessels [1]. Thus, we cannot conclude
that quenching of nitric oxide by superoxide is responsible
for reducing acetylcholine-mediated vascular relaxation in
epineurial arterioles. There is an increase in oxidative stress
in high-fat fed rats as evidence by the increase of markers
of oxidative stress in the serum that can be corrected by
treatment with AVE7688 and to a lesser extent with Enalapril
or Candoxatril. It is thought that a primary source of reactive
oxygen species in the vasculature derived from obese modelsJournal of Obesity 7
is NAD(P)H oxidase [51, 52]. We have demonstrated that
epineurial arterioles from diabetic rats generate reactive oxy-
gen species and the primary source is the mitochondria [53].
We propose that in addition to increased oxidative stress
othermechanismsmayberesponsibleformicrovasculardys-
functioninobesity.Oneofthesemechanismsistheincreased
expression/activity of neutral endopeptidase [20]. We have
shown that diet-induced obesity causes an increase in the
expression of neutral endopeptidase in epineurial arterioles
[1]. In addition, it has been shown that hyperlipidemia and
hyperglycemia increases neutral endopeptidase activity in
human microvascular endothelial cells [6]. In these studies,
we propose that AVE7688, Candoxatril, and to a lesser
extent Enalapril may be protecting vascular reactivity and
neural function by inhibiting neutral endopeptidase and the
degradation of C-type natriuretic peptide and calcitonin
gene-related peptide [11–13, 20].
5. Conclusion
Feeding rats a high-fat diet causes weight gain, impaired
glucose tolerance, increased markers of oxidative stress,
and vascular and sensory nerve dysfunction. Each of these
obesity-induced pathogenic conditions was prevented by
treating the high-fat fed rats with AVE7688 and treatment
with AVE7688 was generally more eﬀective than treatments
with Enalapril or Candoxatril. Thus, we conclude that dual
inhibition of angiotensin converting enzyme and neutral
endopeptidase may be more eﬀective than monotherapy in
reducing insulin resistance and the complications associated
with diet induced obesity.
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